Press Releases September 3, 2026 04:05 PM

Spyre Therapeutics to Participate in Upcoming September Investor Conferences

Spyre Therapeutics Announces Participation in Multiple Investor Conferences in September 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SYRE

Spyre Therapeutics, a clinical-stage biotechnology company specializing in immunology therapies, announced its management team's participation in several upcoming investor conferences in September 2026. The company aims to update investors on its pipeline developments and strategic initiatives, including investigational extended half-life antibodies.

Spyre Therapeutics to Participate in Upcoming September Investor Conferences
SYRE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Spyre Therapeutics will present at three major investor conferences in September 2026: Citi BioPharma Back to School, Wells Fargo Healthcare, and Stifel Immunology and Inflammation Forum.
  • The company's pipeline focuses on next-generation immunology therapies targeting specific pathways such as integrin α4β7, TL1A, IL-23, and IL-17A/F, with an emphasis on improved disease control and treatment simplicity.
  • Management will conduct one-on-one investor meetings and provide live webcasts and event replays accessible on their investor website.
  • Sector Impacted: Biotechnology, Pharmaceuticals, Healthcare Investment.

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences:

Event: Citi 2026 BioPharma Back to School Conference – New York
Date: Wednesday, September 9, 2026
Fireside Time: 10:00 am ET

Event: Wells Fargo 21st Annual Healthcare Conference – Boston
Date: Thursday, September 10, 2026
Fireside Time: 8:00 am ET

Event: Stifel 2026 Virtual Immunology and Inflammation Forum
Date: Wednesday, September 23, 2026
Fireside Time: 8:30 am ET

Members of the Spyre management team will also host one-on-one investor meetings during the conferences.

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, visit Spyre's website at www.spyre.com.

For Investors:     
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
[email protected]


Risks

  • As a clinical-stage biotechnology firm, Spyre faces typical development risks including clinical trial outcomes and regulatory approvals that could affect future growth and valuation.
  • Market liquidity risk associated with investor perception at these conferences; failure to meet investor expectations could limit capital raising opportunities.
  • Competitive risk in the immunology drug development sector, where multiple companies pursue similar targets, potentially impacting Spyre's market share and valuation.

More from Press Releases

Tenable Uses OpenAI GPT Cyber Models to Help Defenders Inspect Community-Built AI Components Sep 3, 2026 XTEND Reality Expansion Ltd. and JFB Construction Holdings Complete Business Combination, Raising $110 Million in Total Capital Sep 3, 2026 Freshworks Announces Inducement Grant under Listing Rule 5635(C)(4) of the Nasdaq Stock Market Sep 3, 2026 Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS Sep 3, 2026 Rogers and Quebecor Agree to New 12-Year Sublicensing Deal for National NHL Games in French Sep 3, 2026